Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 5Phase 1/2 3Phase 3 2

Status

Terminated 3Completed 3Active not recruiting 3Unknown 2Not yet recruiting 2Recruiting 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Neurofibromatosis 1 3Pain 1Neurofibroma, Plexiform 1Astrocytoma 1

Interventions

pembrolizumab 70Nivolumab 36Cyclophosphamide 34Carboplatin 28Dexamethasone 23Specimen Handling 22Paclitaxel 22Lenalidomide 22durvalumab 19Radiotherapy 19Gemcitabine 19venetoclax 18Magnetic Resonance Spectroscopy 18Doxorubicin 17Rituximab 16fludarabine 15Ipilimumab 15Bevacizumab 15Cisplatin 14Biopsy 14atezolizumab 13Etoposide 13Vincristine 12Pemetrexed 12belantamab mafodotin 11Docetaxel 11Calcium Dobesilate 11Azacitidine 11olaparib 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Active not recruiting × AZD 6244 × Clear all
NCT01362803 2026-06-01

AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
99 enrolled 1 FDA
CNS

Neurofibromatosis 1, Pain, Neurofibroma, Plexiform

NCT01089101 2026-05-13

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
217 enrolled
CNS

Astrocytoma, Neurofibromatosis 1

NCT05309668 2025-12-18

SPRINKLE

AstraZeneca

Phase 1/2 Active not recruiting
36 enrolled 37 charts
CNS

Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡